Tarlatamab Clinical Trials
16 recruitingDrug
Phase 210Phase 15Phase 33
Showing 1–16 of 16 trials
Recruiting
Phase 1Phase 2
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Amgen330 enrolled150 locationsNCT07005128
Recruiting
Phase 1Phase 2
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
GliomaCNS Tumor, AdultCNS Tumor, Childhood
Centre Leon Berard70 enrolled11 locationsNCT07243470
Recruiting
Phase 2
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Extensive Stage Lung Small Cell Cancer
ETOP IBCSG Partners Foundation48 enrolled19 locationsNCT07203053
Recruiting
Phase 2
A Study of Tarlatamab for People With Prostate Cancer
Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center32 enrolled10 locationsNCT07111507
Recruiting
Phase 3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Small Cell Lung CancerLimited Stage Small Cell Lung Cancer
Amgen400 enrolled204 locationsNCT06117774
Recruiting
Phase 2
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
Neuroendocrine Carcinomas (NEC)Neuroendocrine Carcinoma of PancreasNeuroendocrine Carcinoma of Prostate
Inkeun Park60 enrolled4 locationsNCT06893783
Recruiting
Phase 1
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Amgen380 enrolled19 locationsNCT07037758
Recruiting
Phase 2
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Extensive Stage Lung Small Cell Carcinoma
Asrar Alahmadi39 enrolled1 locationNCT07423585
Recruiting
Phase 3
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique129 enrolled40 locationsNCT06937905
Recruiting
Phase 1
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer
Amgen200 enrolled36 locationsNCT06898957
Recruiting
Phase 2
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Fundación GECP37 enrolled20 locationsNCT07242547
Recruiting
Phase 2
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Advanced Neuroendocrine Carcinomas of The Digestive SystemAdvanced Neuroendocrine Carcinomas Unknown Primary Origin
Grupo Espanol de Tumores Neuroendocrinos87 enrolled19 locationsNCT07061080
Recruiting
Phase 1
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Amgen220 enrolled30 locationsNCT06598306
Recruiting
Phase 2
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NECMetastatic/Locally Advanced High-grade MTC
Gustave Roussy, Cancer Campus, Grand Paris40 enrolled1 locationNCT07016230
Recruiting
Phase 2
Study of How Safe and Effective Tarlatamab is in Brain Cancers
Astrocytic TumorOligodendroglial Tumor
University Health Network, Toronto44 enrolled1 locationNCT06776250